Who Paid My Doc
Michael Schmerin
New York, NY Medical Doctor
NPI 1700815529 CMS profile 259064
1060 Park Ave, New York, NY 10128
General payments
$7,130
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Michael Schmerin of New York, NY is reported in the CMS Open Payments database as having received $7,130 across 8 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $4,682 | 1 | |
| 2020 | General | $2,417 | 2 | |
| 2019 | General | $31 | 5 |
Beside peers
- Michael Schmerin
- New York median
- Middle half of New York
- National median
In program year 2025, general payments to Michael Schmerin were reported at $0. Among 69,423 New York profiles paid that year, the median was $180 and the middle half received between $58 and $640.
Show as a table
| Year | Michael Schmerin | New York median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $31 | $175 | $53–$665 | $163 |
| 2020 | $2,417 | $122 | $37–$426 | $114 |
| 2021 | $0 | $144 | $44–$514 | $132 |
| 2022 | $0 | $160 | $51–$578 | $149 |
| 2023 | $4,682 | $170 | $54–$593 | $160 |
| 2024 | $0 | $173 | $56–$618 | $164 |
| 2025 | $0 | $180 | $58–$640 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 18 drugsPart D claims
406
Drug cost
$90,290
Branded share of claims
32.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Creon Lipase/Protease/Amylase | Brand | 18 | $31,318 | |
| Mesalamine | Generic | 44 | $21,151 | |
| Linzess Linaclotide | Brand | 16 | $14,943 | |
| Ozempic Semaglutide | Brand | 11 | $10,480 | |
| Dexlansoprazole Dr Dexlansoprazole | Brand | 17 | $3,247 | |
| Budesonide Ec Budesonide | Brand | 13 | $1,871 | |
| Dicyclomine Hcl | Generic | 84 | $1,581 | |
| Synthroid Levothyroxine Sodium | Brand | 11 | $1,021 | |
| Cholestyramine Cholestyramine (With Sugar) | Brand | 18 | $918 | |
| Famotidine | Generic | 23 | $872 |
The 10 drugs with the highest cost, of 18 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.
Records
8 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.